

Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil

William Marciel de Souza ^{1*}, Lewis Fletcher Buss ^{2*}, Darlan da Silva Candido ^{3*}, Jean-Paul Carrera ^{3,4*}, Sabrina Li ^{5*}, Alexander E. Zarebski ³, Rafael Henrique Moraes Pereira ⁶, Carlos A. Prete Jr ⁷, Andreza Aruska de Souza-Santos ⁸, Kris V. Parag ⁹, Maria Carolina T.D. Belotti⁷, Maria F. Vincenti-Gonzalez ¹⁰, Janey Messina ^{5,11}, Flavia Cristina da Silva Sales ², Pamela dos Santos Andrade ², Vítor Heloiz Nascimento ⁷, Fabio Ghilardi ², Leandro Abade ³, Bernardo Gutierrez ^{3,12}, Moritz U. G. Kraemer ^{3,13,14}, Carlos K.V. Braga ⁶, Renato Santana Aguiar ¹⁵, Neal Alexander ¹⁶, Philippe Mayaud ¹⁷, Oliver J. Brady ^{15,18}, Izabel Marcilio ¹⁹, Nelson Gouveia ²⁰, Guangdi Li ²¹, Adriana Tami ¹⁰, Silvano Barbosa de Oliveira ²², Victor Bertollo Gomes Porto ²², Fabiana Ganem ²², Walquiria Aparecida Ferreira de Almeida ²², Francieli Fontana Sutile Tardetti Fantinato ²², Eduardo Marques Macário ²³, Wanderson Kleber de Oliveira ²³, Mauricio L. Nogueira ²⁴, Oliver G. Pybus ³, Chieh-Hsi Wu ^{25*}, Julio Croda ^{23,26,27,28*#}, Ester C. Sabino ^{2*}, Nuno Rodrigues Faria ^{3,29*#}

* These authors contributed equally

Corresponding author

1. Centro de Pesquisa em Virologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil.

2. Instituto de Medicina Tropical da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.

3. Department of Zoology, University of Oxford, Oxford, UK.

4. Department of Research in Virology and Biotechnology, Gorgas Memorial Institute of Health Studies, Panama City, Panama.

- 25 5. School of Geography and the Environment, University of Oxford, Oxford, UK.
- 26 6. Institute for Applied Economic Research (IPEA), Brasília, Brazil.
- 27 7. Escola Politécnica da Universidade de São Paulo, São Paulo, Brazil.
- 28 8. Brazilian Studies Programme, Latin American Centre, University of Oxford, Oxford, UK.
- 29 9. MRC Centre for Global Infectious Disease Analysis, Imperial College London, UK.
- 30 10. University of Groningen, University Medical Center Groningen, Department of Medical
- 31 Microbiology and Infection Prevention, Groningen, Netherlands.
- 32 11. Oxford School of Global and Area Studies, University of Oxford, Oxford, UK.
- 33 12. School of Biological and Environmental Sciences, Universidad San Francisco de Quito
- 34 USFQ, Quito, Ecuador.
- 35 13. Harvard Medical School, Harvard University, Boston, MA, USA.
- 36 14. Boston Children's Hospital, Boston, MA, USA.
- 37 15. Departamento de Genética, Ecologia e Evolução, Instituto de Ciências Biológicas,
- 38 Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
- 39 16. MRC Tropical Epidemiology Group, Department of Infectious Disease Epidemiology,
- 40 Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical
- 41 Medicine, London, UK.
- 42 17. Department of Clinical Research, Faculty of Epidemiology and Population Health,
- 43 London School of Hygiene & Tropical Medicine, London, UK.
- 44 18. Centre for the Mathematical Modelling of Infectious Diseases, Department of Infectious
- 45 Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
- 46 19. Núcleo de Vigilância Epidemiológica do Hospital das Clínicas da Faculdade de Medicina,
- 47 Universidade de São Paulo, São Paulo, Brazil.
- 48 20. Departamento Medicina Preventiva, Faculdade de Medicina da Universidade de São
- 49 Paulo, São Paulo, Brazil.

21. Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha 410078, China.
22. Secretariat of Health Surveillance, Department of Immunization and Communicable Diseases, Brazilian Ministry of Health, Brasília, Brazil.
23. Secretariat of Health Surveillance, Brazilian Ministry of Health, Brasília, Brazil.
24. Faculdade de Medicina de São José do Rio Preto, São Jose do Rio Preto, Brazil.
25. Mathematical Sciences, University of Southampton, Southampton, UK.
26. Laboratório de Pesquisa em Ciências da Saúde, Universidade Federal da Grande Dourados, Dourados, Brazil.
27. Fundação Oswaldo Cruz, Campo Grande, Mato Grosso do Sul, Campo Grande, Brazil.
28. Department of Epidemiology of Microbial Diseases, Yale University School of Public Health, New Haven, USA.
29. Department of Infectious Disease Epidemiology, Imperial College London, London, UK.

Corresponding authors:

Nuno Rodrigues Faria, PhD

Email: nfaria@ic.ac.uk

Julio Croda, MD PhD

Email: juliocroda@gmail.com

Abstract

The first case of COVID-19 was detected in Brazil on February 25, 2020. We report and contextualize epidemiological, demographic, and clinical findings for COVID-19 cases during the first three months of the epidemic. By May 31, 2020, 514,200 COVID-19 cases, including 29,314 deaths had been reported in 75.3% (4,196 of 5,570) of municipalities across all five administrative regions of Brazil. R_0 for Brazil was estimated at 3.1 (95% BCI 2.4–5.5), with a higher median but overlapping credible intervals compared to some other seriously affected countries. A positive association between higher per-capita income and COVID-19 diagnosis was identified. Further, the severe acute respiratory infection cases with unknown aetiology were associated with lower per capita income. Co-circulation of six respiratory viruses was detected but at very low levels. These findings provide a comprehensive description of the ongoing COVID-19 epidemic in Brazil and may help guide subsequent measures to control virus transmission.

Introduction

Coronavirus disease 2019 (COVID-19) is a severe acute respiratory infection that emerged in early December 2019 in Wuhan, China¹. The outbreak was declared a Public Health Emergency of International Concern (PHEIC) by the World Health Organization (WHO) on January 30, 2020. COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an enveloped, single-stranded positive-sense RNA virus that belongs to the *Betacoronavirus* genus, *Coronaviridae* family². SARS-CoV-2 is closely related genetically to bat-derived SARS-like coronaviruses³. Human-to-human transmission occurs primarily via respiratory droplets and direct contact, similar to human influenza viruses, SARS-CoV and Middle East Respiratory Syndrome virus (MERS-CoV)⁴. The most commonly reported clinical symptoms are fever, dry cough, fatigue, dyspnoea, anosmia, ageusia, or some combination of these^{1,4,5}. As of June 16, 2020, more than 7.9 million cases have been confirmed worldwide, resulting in 434,796 deaths⁶.

Brazil declared COVID-19 as a national Public Health Emergency (PHE) on February 3, 2020⁷. After the development of a national emergency plan and the early establishment of molecular diagnostic facilities across Brazil's network of public health laboratories, the country reported its first confirmed COVID-19 case on February 25, 2020, in a traveller returning to São Paulo from northern Italy⁸. São Paulo is the largest city in South America and no other Brazilian city receives a greater proportion of international flights⁹. Currently, Brazil has one of the fastest-growing COVID-19 epidemics in the world, now accounting for 1,864,681 cases and 72,100 deaths, comprising over 55% of the total number of reported cases in Latin America and Caribbean (as of July 14, 2020)⁶. About 21% of Latin American and Caribbean populations are estimated to be at risk of severe COVID-19 illness¹⁰. The region has been experiencing large outbreaks, with growing epidemics in Brazil, Peru, Mexico, Chile, Colombia, Panama, and possibly Venezuela and Nicaragua, amidst growing

109 concerns on testing capacity for COVID-19¹¹⁻¹⁴. Preparedness for laboratory surveillance of
110 SARS-CoV-2 in Latin America is centred around a network of national reference influenza
111 surveillance laboratories that is facing several challenges, including shortage of reagents and
112 equipment¹⁵.

113 Conscious of the challenges associated with surveillance since the beginning of the
114 epidemic in Brazil, here we focus on two main objectives. First, we contextualize the
115 Brazilian SARS-CoV-2 epidemic by comparing local transmission dynamics with those
116 observed in selected other countries. Second, we use geospatial data related to confirmed
117 COVID-19 cases and severe acute respiratory infection (SARI) cases with unknown
118 aetiology to evaluate the relationship between socio-economic factors and COVID-19
119 distribution.

Results

Contextualizing COVID-19 data notification systems in Brazil

On January 22, 2020, more than one month before the first case in Brazil, the Brazilian Ministry of Health implemented the REDCap platform to notify prospective suspected, probable, and confirmed COVID-19 cases (see **Methods** for case definitions), as part of early response to the pandemic¹⁶. By March 27, 2020, the REDCap system was discontinued (**Fig. 1**). Since then, mild-COVID-19 cases started to be notified on e-SUS-VE (e-SUS Vigilância Epidemiológica), a new national COVID-19 notification system and hospitalised COVID-19 cases started to be recorded on a pre-existing SIVEP-Gripe system. The SIVEP-Gripe system has been in use since 2009 (influenza H1N1 2009 pandemic) and has since centralized the notification of respiratory viruses and SARI for the Brazilian Ministry of Health (**Fig. 1**). Both the e-SUS-VE and SIVEP-Gripe include suspected and confirmed COVID-19 cases by public health and private services (primary and emergency care). These two notification systems (e-SUS-VE and SIVEP-Gripe) are inter-related on the *Portal do COVID-19* website (<https://covid.saude.gov.br/>), which summarises daily the aggregated counts from both platforms.

SARS-CoV-2 notification in Brazil: international transmission to rapid internal dissemination

We analysed a total of 514,200 SARS-CoV-2 cases from the *Portal do COVID-19* website (SIVEP-Gripe, and e-SUS VE databases combined) that were confirmed by molecular diagnostic and clinical epidemiological criteria by May 31, 2020 (see Materials and Methods). Cases were reported in 75.3% (4,196 of 5,570) of municipalities across all five administrative regions of Brazil and included 206,555 (40.2%) recovered patients, and 29,314 fatal (17.5%) COVID-19 cases (**Fig. 2A**). We further analysed a total of 1,468 confirmed

cases from the REDCap system, including 342 imported cases with associated travel history information. After excluding cases involving with that travelled to multiple countries before entering Brazil ($n=56$) and that had an unknown country of origin ($n=16$). The self-reported countries of infection for cases acquired abroad until March 19, 2020 were USA (28.6%, $n=76$), Italy (24.4%, $n=65$), and the United Kingdom (10.5%, $n=28$) and Spain (8.3%, $n=22$) (**Extended Data Fig. 1**). The first reported case (SPBR1) was reported on February 25, 2020 in the municipality of São Paulo, the fourth most populous urban area worldwide. Following the first notifications of COVID-19 in Brazil's largest population centres, we find that SARS-CoV-2 subsequently spread to municipalities with smaller population sizes (**Fig. 2B**). Until May 31, 2020, most confirmed cases and deaths were reported in the states of São Paulo (109,698 cases and 7,615 deaths), Rio de Janeiro (53,388 cases and 5,344 deaths), Ceará (48,489 cases and 3,010 deaths) and Amazonas (41,378 cases and 2,052 deaths), which together account for 49.2% of all cases and 61.5% of deaths in Brazil (**Fig. 2c**).

Basic reproduction number (R_0) of SARS-CoV-2 in Brazil and comparison countries

To estimate the basic reproduction number (R_0) of SARS-CoV-2 in Brazil, daily confirmed cases in São Paulo, Rio de Janeiro, Ceará and Amazonas states were compiled from the Ministry of Health (for specification of the time-windows used in the analyses see **Extended Data Fig. 2**). For comparison, we compiled time series of confirmed cases in several European countries from the Johns Hopkins Coronavirus Resource Center (<https://coronavirus.jhu.edu/>, see also **Extended Data Fig. 3**). We found that São Paulo, Rio de Janeiro and Amazonas were characterized by similar R_0 values of 2.9 (95% Bayesian credible interval, BCI, 2.2–5.1), 2.9 (95% BCI 2.2–4.9) and 2.6 (95% BCI 2.0–4.5). However, for Ceará, estimated R_0 was considerably lower, 1.9 (95% BCI 1.5–3.0) (**Fig. 3**, **Extended Data Fig. 1**). This finding could be a result of the small window between the first

notified cases and the early implementation of non-pharmaceutical interventions (NPIs) in this state (**Supplementary Table 1, Extended Data Fig. 2**). On a national scale, the estimated R_0 for Brazil was slightly higher than that of the Brazilian states considered in this study, with a median of 3.1 (95% BCI 2.4–5.5), and also slightly higher than R_0 values estimated for other severely affected countries: Spain (2.6, 95% BCI 2.0–4.6), France (2.5, 95% BCI 1.9–4.4), United Kingdom (2.6, 95% BCI 2.0–5.1) and Italy (2.5, 95% BCI 2.0–4.4) (**Fig. 3**). While the incidence curves for European countries have consistently flattened and declined after the implementation of NPIs (suggesting R_0 has fallen below one), Brazil's daily incidence curve has continued to increase (**Fig. 2A and Extended Data Fig. 4**).

Severe acute respiratory infections (SARI) mostly reflect COVID-19 cases

In the early-phase of the COVID-19 epidemic in Brazil, we analysed the results for other respiratory pathogens tested in Brazil as part of the differential diagnosis by Central Public Health Laboratories and National Influenza Centres (Brazilian Ministry of Health) obtained from a REDcap platform¹⁷ designed for COVID-19. The respiratory viruses most frequently identified between January 2020 and March 27, 2020, in patients with suspected but negative diagnosis of COVID-19 were influenza A virus (347 [14.3%] of 2,429 tested cases), influenza B virus (251 [10.3%] of 2,429) and human rhinovirus (136 [5.6%] of 2,429). We found co-detection of SARS-CoV-2 with six other respiratory viruses, the most frequently were influenza A (11 [0.5%] of 2,429) and human rhinovirus (6 [0.2%] of 2,429) (**Extended Fig. 7**).

The SIVEP-Gripe system started reporting hospitalised COVID-19 cases in early March 2020 (epidemiological week 10) (**Fig. 4**). In this system, the number of tested cases is unavailable. We found that the peak of influenza confirmed cases ($n=447$) occurred at

epidemiological week 12 (15-21 March 2020). During the same week 12, we detected an 8.5-fold increase in total cases attributed to SARS-CoV-2 ($n=3,789$) and a 9.9-fold increase in total cases notified as SARI with unknown aetiology ($n=4,424$) (**Fig. 4**). From January to May 31, 2020, a total of 2,136 influenza cases and 272 cases caused by other respiratory pathogens including human respiratory syncytial virus, human rhinovirus, adenovirus, metapneumovirus were notified in the SIVEP-Gripe database. The low observed incidence of influenza and other respiratory viruses may be influenced by limited testing for these viruses during this period. Although NPIs may have an impact in reducing influenza virus transmission, this does not necessarily reflect a lower co-circulation of other respiratory viruses¹⁸.

Socio-economic differences are associated with COVID-19 diagnosis

Until 31 May 2020, a total of 73,648 COVID-19 confirmed cases and 168,001 SARI cases with unknown aetiology were notified in the SIVEP-Gripe system. We hypothesized that the 2.3-fold increase of SARI cases with unknown aetiology was associated with differential access to healthcare due to socio-economic factors.

We focus on the Metropolitan Region of São Paulo (MRSP) that has a population of 23 million inhabitants across 6 sub-regions (Central, West, North, East, Southeast and Southwest) and 39 municipalities (**Fig. 5A**). To test this hypothesis, we obtained *per capita* income at the census tract level (typically 150-300 households) in the MRSP, based on the residential address of each case. We then linked this information to each patient's final diagnosis outcome: COVID-19 confirmed case or SARI with unknown aetiology. While the income distribution of SARI cases with unknown aetiology was similar to that of the MRSP over the whole period (**Fig. 5B**), we observed that the income distribution individuals conformed to be COVID-19-cases confirmed by laboratory and clinical criteria was initially

higher and decreased over time towards the distribution for the whole of the MRSP by epidemiological week 21 (**Fig. 5B**). Importantly, we found that the log odds of one or more confirmed COVID-19 case per census tract increased with per capita income in epidemiological weeks 12 and 22 (likelihood ratio test [LRT] P -value <0.001 (**Fig. 5B** and **Supplementary Table 2**). This provides statistical evidence of an association between confirmed COVID-19 diagnosis and *per capita* income, suggesting a socio-economic difference in access to COVID-19 diagnosis in the MRSP. For reference, we also provide a map of per capita income (**Fig. 5A**) and population density in each census tract (**Extended Data Fig. 8**).

We conducted a geospatial analysis to understand the distribution of relative risk of observing a COVID-19 case or an SARI cases with unknown aetiology in the MRSP, using a Bayesian method and adjusted for spatial and non-spatial effects defined by Besag-York-Mollié model¹⁹ (**Fig. 5**). Our estimates show an increase in the relative risk of COVID-19 diagnosis in higher income census tracts between epidemiological weeks 12 to 21, especially in the central region of the MRSP (**Figs. 5A and 5C**). We observed a similar trend in the relative risk of SARI cases with unknown aetiology among residents of the central region. However, there is also increased probability of SARI cases with unknown aetiology in the southwest, west, north, and south sub-regions, where income per capita is typically lower. Overall, the relative risk of SARI cases with unknown aetiology is more spatially widespread in the MRSP than of confirmed COVID-19 cases (**Fig. 5C**).

The relative risk of SARI cases with unknown aetiology compared to confirmed COVID-19 cases in the central region of the MRSP decreases through time likely as a response to several NPIs implemented throughout the state of São Paulo (see **Supplementary Table 1**). By week 16, one month after the start of the NPIs in São Paulo, we detected an increased risk particularly of SARI cases with unknown aetiology outside the central region

of the MRSP, especially in the southwest region. SARI cases with unknown aetiology risk was also high in the east region. By week 21, the risk remained high throughout the central region and SARI cases with unknown aetiology risk decreased in the east region, possibly as a result of interventions targeting the reduction of SARS-CoV-2 transmission.

Demographics and characteristics of COVID-19 hospitalised and fatal cases in Brazil

Analysis of the age-sex structure of 67,180 confirmed COVID-19 cases notified on the SIVEP-Gripe system revealed a high proportion (44,027 [65.5%] of 67,180) of confirmed COVID-19 infections in middle or older-age individuals (≥ 50 years of age) and a lower proportion (1,454 [2.2%] of 67,180) in younger age groups (≤ 20 years of age) (**Fig. 6A**). The median age was 59 years (IQR = 44–72). The majority (38,654 [57.5%] of 67,180) were male. Similarly, 59% (14,498 of 24,519) of COVID-19 deaths were in men, and 85% (20,916 of 24,519) were in people aged ≥ 50 years. A total of 2.95% (1,983 of 67,180) cases were reported as nosocomial transmission, defined as a COVID-19 case acquired after hospitalization. Overall, 116 newborns (\leq one month old), 381 infants (≥ 1 to 12 month-old), 518 children (≥ 1 to 12 years old), and 258 adolescents (≥ 12 to 17 years of age) were diagnosed with COVID-19. In addition, 740 patients were pregnant, 61 in the first trimester, 172 in the second trimester, 447 in the third trimester, and 60 had missing gestational age.

By 31 May 2020, 91% (67,042 of 73,649) of patients with COVID-19 notified in the SIVEP-Gripe system had been hospitalized. Of these, 30.3% (22,332 of 73,649) were admitted to an intensive care unit (ICU). The median length of ICU stay for COVID-19 patients was five days (IQR, 2–10, range: 0–65 days), based on the ICU admission and discharge dates of 8,240 confirmed cases. Most symptoms reported by COVID-19 patients were cough (56,681 [85.2%] of 66,514 without missing data), fever (51,312 [79.6%] of

65,310) and dyspnoea (51,312 [76.6%] of 65,310) (**Fig. 6B**). These three symptoms compose part of the case definition of SARI in Brazil. In addition, 68% (40,806 of 60,400) of COVID-19 cases were hypoxic (O_2 saturation < 95%) reflecting the overall severity of cases notified on SIVEP-Gripe (as shown in **Fig. 1**). The most prevalent comorbidities were cardiovascular disease (23,085 [66.5%] of 34,693 without missing data) and diabetes (17,271 [54.5%] of 31,672) (**Fig. 6A**). Among the COVID-19 patients, older age groups tended to have a higher proportion of comorbidities than younger age groups in different outcomes (**Fig. 6C**). The proportions of the general Brazilian population with cardiovascular disease and diabetes are 4.2%, and 6.2%, respectively²⁰. A total of 83.7% (17,921 of 21,414 with complete comorbidity information) confirmed COVID-19 cases had at least one comorbidity (see **Supplementary Table 2** for information on data completeness).

Discussion

While the COVID-19 epidemic in Brazil continues to grow, details of its transmission potential and clinical and epidemiological characteristics remains poorly understood. We estimate a higher median transmission potential, R_0 of 3.1 (2.4–5.5), of SARS-CoV-2 in Brazil compared with Italy, UK, France, and Spain, which have point estimates of R_0 varying from 2.5 to 2.6, however the credible intervals overlap substantially. We have also observed rapid spread of COVID-19 through the country, with more populated and better-connected municipalities being affected earlier and less populated municipalities being affected at a later stage of the epidemic. In the São Paulo metropolitan region, we found a higher risk of diagnosed COVID-19 cases in census tracts with higher per capita income during the early-phase of COVID-19 epidemic but also as weeks progressed. This contrasts with the wider spread of SARI cases among sub-regions with lower per capita income. Our results provide new insights into the Brazilian COVID-19 epidemic and highlight the high transmission potential of SARS-CoV-2 in the country, the role of its large urban centres, and the lack of lockdown, the challenges in notification and non-equitable access to testing/diagnostic as factors potentially contributing to the rapid and sustained spread of the epidemic in Brazil.

Recent estimates of R_0 at the beginning of the COVID-19 epidemic in Brazil have suggested that an infected individual would infect on average three or four others²¹. The credible intervals of our estimates broadly overlap with these observations and are lower compared to previously published estimates for Brazil²². As a comparison, reproduction number in Peru have been estimated at around 2.3 (2.0–2.5)²³. Since the start of the epidemic in Brazil, several types of NPI have been adopted with varied success by the country's 27 federal units and 5,596 municipalities. Virus transmission seems to have dropped substantially in most affected states²¹ and also in the city of São Paulo²⁴. However, the estimated reproduction number remains above one^{21,24}. Thus, only mitigation (and not

suppression) of the epidemic has been achieved so far, which has been linked to substantial excess deaths due to poorer health care available^{25,26}. Closer surveillance of viral transmission at the local scales and an assessment of the impact of the different control measures on COVID-19 transmission will help to determine a “optimal” mitigation strategy to minimize infections and reduce healthcare demand in Brazil. Moreover, continued monitoring of the genetic diversity of the virus lineages circulating in Brazil²⁴ will be important, as recent data suggests that virus diversity may play a role in virus transmissibility^{27,28}.

We find that 65.5% of notifications in the SIVEP-Gripe system, which includes most severe COVID-19 cases are from patients aged ≥ 50 years of age. This observation is remarkably similar to current estimates for Latin America¹⁰, where 65% of the individuals ≥ 50 years of age have been estimated to be at high risk of severe COVID-19, defined as individuals with at least one condition who would require hospitalisation if infected. Moreover, we find that 57% and 59% of the severe COVID-19 cases and deaths (respectively) notified in SIVEP-Gripe were male, and that the most frequent comorbidities were cardiovascular disease and diabetes. Overall 84% of SIVEP-Gripe notifications had at least one underlying condition; of these, 21% ($n=9,471/45,480$) are included in the working age (16 to 65 years of age). Moreover, only 2.6% ($n=1892/73,673$) of the COVID-19 confirmed cases notified in the SIVEP-Gripe system include occupation. Information on socio-economic determinants as well as occupation and race/ethnicity are critical²⁹ as this allows to prioritisation of control efforts, for example towards healthcare workers and patients attending hospitals³⁰ or work settings³¹.

Our data uncovers a socio-economic bias in testing and diagnostics in current surveillance guidelines and suggests that the number of notified confirmed case counts may

substantially underestimate the number of cases in the general population, particularly in regions of lower socio-economic status. Socio-economic differences are associated with access to healthcare³² and should be taken into account when designing targeted interventions. We find that the proportion of SARI cases with unknown aetiology to confirmed COVID-19 cases has increased across the entire country (as of June 15, 2020, the number of notified SARI cases with unknown aetiology is nearly 2-fold greater than confirmed COVID-19 cases). Based on clinical and epidemiological grounds, it is likely that many SARI cases with unknown aetiology are caused by SARS-CoV-2. In order rigorously establish the contribution of non-SARS-CoV-2 infections to the SARI cases, we would need additional denominator data to understand the level of testing for these viruses, i.e., the negative test results. Our findings with regards to socio-economic bias are likely to apply to other states and regions of Brazil and highlight the importance of scaling up surveillance and laboratory capacity within Latin America. Indeed, the largest Brazilian serosurvey conducted to date suggests that undetected cases may be seven times higher than reported cases³³.

We further show that SARI cases with unknown aetiology are associated with lower socio-economic status in the Metropolitan Region of São Paulo. The socio-economic disparities observed here were particularly evident at the beginning of the outbreak (**Fig. 5B**). This can be explained in part by (i) the high proportion of early cases in returning travellers with higher income and better access to private laboratories for diagnostics, and (ii) the more limited access to freely available diagnostic screening. For example, between February 25 and March 18, 2020, two thirds (586 [66.9%] of 876) of diagnostic tests were performed in private medical laboratories where costs varied typically between 300-690 Brazilian Reais (BRL) (for context, current minimum monthly salary is 1,045 BRL). Thus, the true burden of the epidemic in lower income neighbourhoods is most likely underestimated. In New York City, for example, poorer neighbourhoods had higher disease burden, driven in part by the

movement of essential workers using public transport during the pandemic³⁴. Data-driven analyses are urgently needed to help tackling health inequities during the ongoing epidemic in Brazil. Strategies to evaluate and control transmission should consider differential assess to COVID-19 diagnosis for lower income populations, changes in notification systems and delays in reporting which are key to accurately determine rates of epidemic growth³⁵. Innovative infectious disease surveillance approaches such as those obtained from aggregated mobility data, when used properly, could help supporting public health actions across the COVID-19 epidemic³⁶⁻³⁹.

Epidemics of COVID-19 and influenza seem to have occurred simultaneously in Brazil (**Fig.4** and **Extended Data Figure 7**) and symptoms overlap between the two infections. We detected co-circulation of eight other respiratory viruses, the most common respiratory infections were influenza A and B, and human rhinovirus. We also detected multiple co-detection of SARS-CoV-2 with other respiratory viruses, such as influenza A, B and human metapneumovirus, which have also been reported elsewhere^{40,41}. Although, co-infections with other respiratory viruses have been reported in other countries⁴²⁻⁴⁴, no difference in clinical disease severity between cases with and without viral co-infection has been observed thus far⁴⁵. The co-circulation of other respiratory pathogens highlights the need of scaling up laboratory and molecular screening of SARS-CoV-2 and other respiratory viruses in public laboratories across Brazil¹⁵. Continued molecular and genomic surveillance will be important to determine patterns of virus transmission and guide public health measures in forthcoming phases of the epidemic^{24,46-48}.

There are several limitations to this study. First, detailed individual-level data were only available for REDcap and SIVEP-Gripe systems, in which many cases had incomplete documentation, particularly regarding comorbidities. Second, our socio-economic analysis was based partially on ecological inference, using the *per capita* income in the census tract of

residence (rather than the actual income of the patients), and assuming the same denominator for each census tract (~300 households). We emphasize that our spatial analysis is prone to methodological constraints caused by ecological fallacy and the modifiable areal unit problem. These constraints are inherent to any spatial analysis of aggregated data. Despite the above-mentioned limitation, census tract corresponds to small areas of analysis, of no more than 300 households but often less than that. Social science literature on Brazil not only highlights the country's socio-economic inequality but also how it is spatially pronounced, for that reason, census tract remains a useful tool to infer *per capita* income in the absence of individual-level data. In addition, our databases were predominantly composed of hospitalised COVID-19 patients, and we were unable to evaluate the rate of hospitalisation among the different socio-economic status. In the future, robust modelling of the relationships between socio-economic factors and disease severity will require a data collection system with detailed information on symptoms/signs and comorbidities both in severe and non-severe cases. Finally, our retrospective study has focused predominantly on symptomatic patients that presented or were referred to health services for testing. Therefore, we are unable and do not attempt to describe the full spectrum of disease, nor can we describe the full epidemiological picture of this epidemic.

In conclusion, we have provided a comprehensive assessment of COVID-19 notification and transmission in Brazil. Our findings provide important context for diagnostic screening and health-care planning, and for future precision studies focussing on the impact of non-pharmaceutical and pharmaceutical interventions, and the effect of social health determinants on COVID-19 transmission.

Methods

Ethical approval and case definitions

This retrospective national study was supported by the Brazilian Ministry of Health and ethical approval was provided by the national ethical review board (Comissão Nacional de Ética em Pesquisa, CONEP), protocol number CAAE 30127020.0.0000.0068.

A patient presenting with an acute respiratory syndrome (fever and at least one sign/symptom of respiratory illness), and (i) history of travel to a location with community transmission of COVID-19, or, (ii) contact with a confirmed or probable COVID-19 case in the 14 days preceding symptom onset, or (iii) absence of an alternative diagnosis that completely explains the clinical presentation⁶ was considered as suspected COVID-19 case.

Initially, a traveller was considered a suspected case only when arriving from China, although the definition of suspected cases associated with travel later included Japan, Singapore, South Korea, North Korea, Thailand, Vietnam and Cambodia (February 21, 2020), Italy, Germany, Australia, United Arab Emirates, Philippines, France, Iran and Malaysia (February 25, 2020), the USA, Canada, Switzerland, United Kingdom and 4 additional countries (March 3, 2020). From March 9, 2020 onwards, the Ministry of Health decided to start testing all hospitalised patients with severe respiratory symptoms, regardless of travel history.

Contact with a confirmed or probable COVID-19 case was defined as face-to-face or direct contact with a COVID-19 case, or direct contact in a health-care setting. Moreover, patients reporting travel to an affected country in the preceding 14 days were considered imported cases. Cases not meeting this criterion were considered to be due to local transmission.

Suspected COVID-19 cases were confirmed by laboratory testing (i.e., molecular diagnostic with real-time quantitative PCR), or by clinical-epidemiological criteria. In the latter case, the classification is used when laboratory testing is inconclusive or unavailable, as recommended by Brazilian Ministry of Health guidelines, dated April 6, 2020⁴⁹, and by the World Health Organization interim guidance, dated March 25, 2020⁵⁰.

Individual-level notification of COVID-19 and SARI cases with unknown aetiology from Brazil

To investigate individual-level diagnostic, demographic, self-reported travel history, place of residence and likely place of infection, differential diagnosis for other respiratory pathogens, as well as clinical details, including comorbidities, we collected three epidemiological data sources: (i) $n = 67,344$ suspected and $n = 1,468$ confirmed cases notified to the REDCap database from February 25 to March 25, 2020; (ii) $n = 73,637$ confirmed SIVEP-Gripe (*Sistema de Informação de Vigilância Epidemiológica da Gripe*) from March 1 to May 31, 2020 (available at <https://shiny.hmg.saude.gov.br/dataset>); and (iii) $n = 514,200$ confirmed cases from aggregated data daily released at the *Portal do COVID-19* (Brazilian Health Ministry) from February 25 to May 31, 2020 (available at www.covid.saude.gov.br/). SIVEP-Gripe system notifies severe acute respiratory infections (SARI), which can be defined as an acute respiratory infection with onset within the last 10 days of fever ($\geq 38^{\circ}\text{C}$) and cough, and typically requires hospitalization (see also **Fig. 1A**).

Basic reproduction number (R_0) estimation

We estimated the basic reproduction number (R_0) for SARS-CoV-2 using time series of confirmed COVID-19 cases at the national and state level: São Paulo, Rio de Janeiro,

Ceará and Amazonas (**Extended Data Fig. 1**). To avoid the impact of non-pharmaceutical interventions (NPI) on R_0 estimates, only data points up to 14 days after the implementation of the strictest interventions were used. As lockdown was not imposed in Brazil, the strictest measure was considered closure of non-essential commerce. For European countries, the date of lockdown was used as NPI date. NPI dates for Brazilian states were collected from state decrees. For Brazil as a whole the NPI date for São Paulo state was used, as by that point most states in Brazil had already closed non-essential commerce. For the European countries, lockdown dates were collected from <https://www.covid19healthsystem.org/mainpage.aspx>.

To test the estimation routine and provide international context, this analysis was replicated on equivalent time series from Italy, Spain, France, and the United Kingdom. Aggregated USA and China epidemiological data were not included due to possible heterogeneity within each country. Daily counts of confirmed cases were modelled with a negative binomial distribution with a mean equal to a fixed portion, ρ , of the total daily number of cases in an exponential model of incidence. The functional form of the incidence model is $\rho R_0 \gamma i_0 e^{(R_0 - 1)\gamma t}$, which comes from an exponential approximation of the early dynamics where individuals cease to be infectious at a rate γ . The factor of $\rho R_0 \gamma$ accounts for the partial observation of the incidence. In this analysis was not accounted for the delay between infection and reporting.

Since ρ and i_0 only appear together, they were unidentifiable, we combine them into a single parameter, ζ . This identifiability issue prevents us from estimating the prevalence without additional information to inform either i_0 or ρ . The analysis was carried out in a Bayesian framework with an uninformative prior distribution on R_0 and an informative prior on the removal rate, all other parameters had weakly-informative prior distributions (details in the **Supplementary Information**, pp. 2-3). The informative prior ensured an individual is infectious for an average of 5 to 14 days⁵¹ (**Supplementary Information, Fig. 5-6**). Standard

diagnostics were used to check whether the Markov Chain Monte Carlo (MCMC) samples were satisfactory. Full details of the model used, the estimation process and convergence of MCMC chains can be found in the **Supplementary Information**, pp. 2-3.

Geospatial analysis of COVID-19 cases and socio-economic status

The average household *per capita* income for the Metropolitan Region of São Paulo (MRSP) was retrieved at the census tract level from the 2010 census (<https://censo2010.ibge.gov.br/>). We geocoded 24,063 COVID-19 cases and 32,914 SARI cases with unknown aetiology from MRSP, which were notified until May 28, 2020. The geo-coding was based on self-reported residential address or postal codes using the Galileo algorithm⁵² and coordinates were confirmed using the Google API.

To elucidate the distribution of COVID-19 cases and SARI cases with unknown aetiology cases, we mapped the mean relative risk of COVID-19 and SARI cases with unknown aetiology at the census tract level for MRSP for three epidemiological weeks (12, 16, and 21). As the observation process was a confounding process and without additional assumptions (e.g. covariates), we cannot disentangle an increase in prevalence from an increase in case ascertainment. The cumulative number of cases in each tract is modelled as a Poisson random variable with a mean specified by the expected number of cases under a null model adjusted by tract specific risk due to spatial and non-spatial effects: the Besag-York-Mollié model¹⁹. Estimates of the risk of COVID-19 diagnosis or SARI cases with unknown aetiology were obtained using approximate Bayesian methods (Integrated Nested Laplace Approximation). A complete specification of the model and the computational methodology can be found in the **Supplementary Information**, pp.1-2.

The association between final diagnostic category (COVID-19 or SARI cases with unknown aetiology) and socio-economic status in the subset of cases in the MRSP with geocoded residential information was evaluated using logistic regression models. We focused on the cases in epidemiological weeks 12, 16 and 22. Within each of those weeks, if a census tract reported any COVID-19 or SARI cases with unknown aetiology, we calculated the proportion of the number of COVID-19 cases. Since most census tracts reported only one case each week, the proportion of COVID-19 of each census tract were mostly either 0 or 1 in a given week. For this reason, we defined two categories: (i) the census tract only reported SARI of unknown etiology, i.e. no COVID-19 cases, (ii) the census tract reported at least one COVID-19 case in the week. We used these two categories as the binary response, and applied logistic regression models to investigate whether income per capita was associated with this response. The analyses were adjusted by the logarithm of the population sizes and the longitude and latitude coordinates of the census tracts. The analysis was performed individually for each of epidemiological weeks 12, 16 and 22. Further details of this analysis can be found in the **Supplementary Information**, pp. 1-2.

511 **Data availability**

512 Datasets of clinical and laboratory data presented in the current study from SIVEP-Gripe and
513 *Portal do COVID-19* database are available at <https://doi.org/10.5061/dryad.n8pk0p2sp>. The
514 REDCap database and geolocation information are available from the corresponding authors
515 upon request and ethical approval.

516

517 **Code availability**

518 The custom code used in this study is available at <https://doi.org/10.5061/dryad.n8pk0p2sp>.

519

520 **Author contributions**

521 W.M.S, L.F.B, D.S.C, R.H.M.P, C.A.P, J.C, J-P.C, V.H.N, A.E.Z, J.M, F.C.S.S, P.S.A, F.G,
522 A.A.S-S, B.G, C-H.W, S.L, N.G, S.B.O, K.V.P, M.C.T.D.B, V.B.G.P, C.K.V.B, F.G,
523 W.A.F.A, F.F.S.T.F, E.M.M and W.K.O collected the epidemiological, spatial and clinical
524 data and processed statistical data. N.R.F, W.M.S, L.F.B, C-H.W, J-P.C, D.C.S, R.H.M.P,
525 J.M, E.C.S, P.M, S.L, L.A, A.A.S-S, G.L, A.T, M.F.V-G, M.U.G.K, R.S.A, N.A, P.M, O.J.B,
526 I.O.M.S, N.G, G.L, O.G.P, A.E.Z, M.L.N, and J.C interpreted the results and wrote the
527 manuscript. All authors read and revised the final manuscript. W.M.S, L.F.B, J.C, and N.R.F
528 are responsible for summarising epidemiological and clinical data.

529

530 **Declaration of interests**

531 The authors declare no competing interests.

532

533 **Acknowledgments**

534 The authors thank the clinicians and epidemiologists for technical support and Lucy Matkin
535 for technical assistance. This work was supported by a FAPESP (2018/14389-0) and Medical
536 Research Council and CADDE partnership award (MR/S0195/1), (<http://caddecentre.org/>).
537 WMS is supported by the São Paulo Research Foundation, Brazil (No. 2017/13981-0 and
538 2019/24251-9). NRF is supported by a Wellcome Trust and Royal Society Sir Henry Dale
539 Fellowship (204311/Z/16/Z). OJB was funded by a Sir Henry Wellcome Fellowship funded
540 by the Wellcome Trust (206471/Z/17/Z). VHN and CAP were supported by FAPESP
541 (2018/12579-7). AEZ and BG are supported by Oxford Martin School. The funders had no
542 role in study design, data collection and analysis, decision to publish or preparation of the
543 manuscript.

544

References

- 1 Huang, C. *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* **395**, 497-506, doi:10.1016/S0140-6736(20)30183-5 (2020).
- 2 Coronaviridae Study Group of the International Committee on Taxonomy of, V. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nature Microbiology*, doi:10.1038/s41564-020-0695-z (2020).
- 3 Lu, R. *et al.* Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet* **395**, 565-574, doi:10.1016/S0140-6736(20)30251-8 (2020).
- 4 Guan, W. J. *et al.* Clinical Characteristics of Coronavirus Disease 2019 in China. *The New England Journal of Medicine*, doi:10.1056/NEJMoa2002032 (2020).
- 5 Livingston, E. & Bucher, K. Coronavirus Disease 2019 (COVID-19) in Italy. *Jama*, doi:10.1001/jama.2020.4344 (2020).
- 6 World-Health-Organization. Coronavirus disease (COVID-2019) situation reports (2020). Available at: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>
- 7 Croda, J. *et al.* COVID-19 in Brazil: advantages of a socialized unified health system and preparation to contain cases. *Revista da Sociedade Brasileira de Medicina Tropical* **53**, e20200167, doi:10.1590/0037-8682-0167-2020 (2020).
- 8 Jesus, J. G. *et al.* Importation and early local transmission of COVID-19 in Brazil, 2020. *Revista do Instituto de Medicina Tropical de Sao Paulo* **62**, e30, doi:10.1590/s1678-9946202062030 (2020).

- 568 9 Candido, D. S., Watts, A., Abade, L., Kraemer, M. U.G., Pybus, O. G., Croda, J., de
569 Oliveira, W., Khan, K., Sabino, E. C., Faria, N. R. Routes for COVID-19 importation
570 in Brazil. *Journal of Travel Medicine* **in press** (2020).
- 571 10 Clark, A., Jit, M., Warren-Gash, C., Guthrie, B., Wang, H. H. X., Mercer, S. W.,
572 Sanderson, C., McKee, M., Troeger, C., Ong, K. L., Checchi, F., Perel, P., Joseph, S.,
573 Gibbs, H. P., Banerjee, A., Eggo, R. M., Centre for the Mathematical Modelling of
574 Infectious Diseases COVID-19 working group. Global, regional, and national
575 estimates of the population at increased risk of severe COVID-19 due to underlying
576 health conditions in 2020: a modelling study. *The Lancet Global health*
577 [https://doi.org/10.1016/S2214-109X\(20\)30264-3](https://doi.org/10.1016/S2214-109X(20)30264-3) (2020).
- 578 11 Burki, T. COVID-19 in Latin America. *The Lancet Infectious Diseases* **20**, 547-548,
579 doi:10.1016/S1473-3099(20)30303-0 (2020).
- 580 12 Cimerman, S., Chebabo, A., Cunha, C. A. D. & Rodriguez-Morales, A. J. Deep
581 impact of COVID-19 in the healthcare of Latin America: the case of Brazil. *The*
582 *Brazilian Journal of Infectious Diseases* **24**, 93-95, doi:10.1016/j.bjid.2020.04.005
583 (2020).
- 584 13 Ezequiel, G. *et al.* The COVID-19 Pandemic: A Call to Action for Health Systems in
585 Latin America to Strengthen Quality of Care. *Int J Qual Health Care*,
586 doi:10.1093/intqhc/mzaa062 (2020).
- 587 14 Miller, M. J., Loaiza, J. R., Takyar, A. & Gilman, R. H. COVID-19 in Latin America:
588 Novel transmission dynamics for a global pandemic? *PLoS Negl Trop Dis* **14**,
589 e0008265, doi:10.1371/journal.pntd.0008265 (2020).
- 590 15 Andrus, J. K. *et al.* Perspectives on Battling COVID-19 in Countries of Latin America
591 and the Caribbean. *The American Journal of Tropical Medicine and Hygiene*,
592 doi:10.4269/ajtmh.20-0571 (2020).

593 16 Croda, J. H. R. & Garcia, L. P. Immediate Health Surveillance Response to COVID-
594 19 Epidemic. *Epidemiol Serv Saude* **29**, e2020002, doi:10.5123/S1679-
595 49742020000100021 (2020).

596 17 Harris, P. A. *et al.* The REDCap consortium: Building an international community of
597 software platform partners. *J Biomed Inform* **95**, 103208,
598 doi:10.1016/j.jbi.2019.103208 (2019).

599 18 WHO. Influenza update (2020).
600 https://www.who.int/influenza/surveillance_monitoring/updates/latest_update_GIP_s
601 [urveillance/en/](https://www.who.int/influenza/surveillance_monitoring/updates/latest_update_GIP_s) (2020).

602 19 Besag, J., York, J. & Mollié, A. Bayesian image restoration, with two applications in
603 spatial statistics. *Annals of the Institute of Statistical Mathematics* **43**, 1-20,
604 doi:10.1007/BF00116466 (1991).

605 20 IBGE. Pesquisa nacional de saúde (2013) Brasil e grandes regiões. (2015).

606 21 Mellan, T. A. *et al.* Report 21: Estimating COVID-19 cases and reproduction number
607 in Brazil. *medRxiv*, 2020.2005.2009.20096701, doi:10.1101/2020.05.09.20096701
608 (2020).

609 22 Caicedo-Ochoa, Y., Rebellon-Sanchez, D. E., Penaloza-Rallon, M., Cortes-Motta, H.
610 F. & Mendez-Fandino, Y. R. Effective Reproductive Number estimation for initial
611 stage of COVID-19 pandemic in Latin American Countries. *International Journal of*
612 *Infectious Diseases* **95**, 316-318, doi:10.1016/j.ijid.2020.04.069 (2020).

613 23 Munayco, C. V. *et al.* Early transmission dynamics of COVID-19 in a southern
614 hemisphere setting: Lima-Peru: February 29th-March 30th, 2020. *Infect Dis Model*,
615 doi:10.1016/j.idm.2020.05.001 (2020).

616 24 Candido, D. d. S. *et al.* Evolution and epidemic spread of SARS-CoV-2 in Brazil.
617 *medRxiv*, 2020.2006.2011.20128249, doi:10.1101/2020.06.11.20128249 (2020).

- 25 Ferguson, N. *et al.* Report 9: Impact of non-pharmaceutical interventions (NPIs) to
reduce COVID19 mortality and healthcare demand. Imperial College COVID-19
Response Team (2020).
- 26 Walker, P. G. T. *et al.* The impact of COVID-19 and strategies for mitigation and
suppression in low- and middle-income countries. *Science*,
doi:10.1126/science.abc0035 (2020).
- 27 Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theil, J., Abfalterer, W.,
Foley, B., Giorgi, E. E., Bhattacharya, T., Parker, M. D., Partridge, D. G., van, C.
M., Freeman, T. M., de Silva, T. I., on behalf of the Sheffield. COVID-19 Genomics
Group, LaBranche, C. C., Montefiori, D. C. Spike mutation pipeline reveals the
emergence of a more transmissible form of SARS-CoV-2. *bioRxiv*
<https://doi.org/10.1101/2020.04.29.069054> (2020).
- 28 Zhang, L. *et al.* The D614G mutation in the SARS-CoV-2 spike protein reduces S1
shedding and increases infectivity. *bioRxiv*, 2020.2006.2012.148726,
doi:10.1101/2020.06.12.148726 (2020).
- 29 Khalatbari-Soltani, S., Cumming, R. G., Delpierre, C. & Kelly-Irving, M. Importance
of collecting data on socioeconomic determinants from the early stage of the COVID-
19 outbreak onwards. *J Epidemiol Community Health*, doi:10.1136/jech-2020-214297
(2020).
- 30 Rivett, L. *et al.* Screening of healthcare workers for SARS-CoV-2 highlights the role
of asymptomatic carriage in COVID-19 transmission. *eLife* **9**,
doi:10.7554/eLife.58728 (2020).
- 31 Park, S. Y. *et al.* Coronavirus Disease Outbreak in Call Center, South Korea.
Emerging Infectious Diseases **26**, doi:10.3201/eid2608.201274 (2020).

642 32 Pereira, R. H. et al. Mobilidade urbana e o acesso ao Sistema Único de Saúde para
643 casos suspeitos e graves de Covid-19 nas vinte maiores cidades do Brasil. 14 Diretoria
644 de Estudos e Políticas Regionais, Urbanas e Ambientais, IPEA (2020).

645 33 Silveira, M. *et al.* Repeated population-based surveys of antibodies against SARS-
646 CoV-2 in Southern Brazil. *medRxiv*, 2020.2005.2001.20087205,
647 doi:10.1101/2020.05.01.20087205 (2020).

648 34 Sy, K. T. L., Martinez, M. E., Rader, B. & White, L. F. Socioeconomic disparities in
649 subway use and COVID-19 outcomes in New York City. *medRxiv*,
650 2020.2005.2028.20115949, doi:10.1101/2020.05.28.20115949 (2020).

651 35 Dehning, J. *et al.* Inferring change points in the spread of COVID-19 reveals the
652 effectiveness of interventions. *Science*, doi:10.1126/science.abb9789 (2020).

653 36 Buckee, C. O. *et al.* Aggregated mobility data could help fight COVID-19. *Science*
654 **368**, 145-146, doi:10.1126/science.abb8021 (2020).

655 37 de Oliveira, S. B. *et al.* Monitoring social distancing and SARS-CoV-2 transmission
656 in Brazil using cell phone mobility data. *medRxiv*, 2020.2004.2030.20082172,
657 doi:10.1101/2020.04.30.20082172 (2020).

658 38 Kraemer, M. U. G. *et al.* The effect of human mobility and control measures on the
659 COVID-19 epidemic in China. *Science* **368**, 493-497, doi:10.1126/science.abb4218
660 (2020).

661 39 Nouvellet, P. *et al.* Report 26: Reduction in mobility and COVID-19 transmission.
662 Imperial College COVID-19 Response Team (2020).

663 40 Wu, X. *et al.* Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with
664 Pneumonia, China. *Emerging Infectious Diseases* **26**, doi:10.3201/eid2606.200299
665 (2020).

666 41 Kim, D., Quinn, J., Pinsky, B., Shah, N. H. & Brown, I. Rates of Co-infection
667 Between SARS-CoV-2 and Other Respiratory Pathogens. *JAMA*,
668 doi:10.1001/jama.2020.6266 (2020).

669 42 Cuadrado-Payan, E. *et al.* SARS-CoV-2 and influenza virus co-infection. *Lancet* **395**,
670 e84, doi:10.1016/S0140-6736(20)31052-7 (2020).

671 43 Wu, X. *et al.* Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with
672 Pneumonia, China. *Emerging Infectious Diseases* **26**, 1324-1326,
673 doi:10.3201/eid2606.200299 (2020).

674 44 Zheng, X. *et al.* Co-infection of SARS-CoV-2 and Influenza virus in Early Stage of
675 the COVID-19 Epidemic in Wuhan, China. *The Journal of infection*,
676 doi:10.1016/j.jinf.2020.05.041 (2020).

677 45 Asner, S. A. *et al.* Clinical disease severity of respiratory viral co-infection versus
678 single viral infection: a systematic review and meta-analysis. *PloS One* **9**, e99392,
679 doi:10.1371/journal.pone.0099392 (2014).

680 46 Black, A., MacCannell, D. R., Sibley, T. R. & Bedford, T. Ten recommendations for
681 supporting open pathogen genomic analysis in public health. *Nature Medicine*,
682 doi:10.1038/s41591-020-0935-z (2020).

683 47 Deng, X. *et al.* Genomic surveillance reveals multiple introductions of SARS-CoV-2
684 into Northern California. *Science*, doi:10.1126/science.abb9263 (2020).

685 48 Lu, J. *et al.* Genomic Epidemiology of SARS-CoV-2 in Guangdong Province, China.
686 *Cell* **181**, 997-1003 e1009, doi:10.1016/j.cell.2020.04.023 (2020).

687 49 Ministerio da Saude, B. Coronavirus COVID-19 Diretrizes para Diagnostico e
688 Tratamento da COVID-19. (2020).

689 50 WHO. *COVID-19 coding in ICD-10*,
690 <<https://www.who.int/classifications/icd/COVID-19-coding-icd10.pdf?ua=1>> (2020).

- 51 Wolfel, R. *et al.* Virological assessment of hospitalized patients with COVID-2019.
Nature, doi:10.1038/s41586-020-2196-x (2020).
- 52 Medel, C. H., Catalan, C. C. Vidou, M. A. F., Perez, E. S. The Galileo Ground
Segment Integrity Algorithms: Design and Performance. *International Journal of
Navigation and Observation* **2008** (2008).

Legend figures

Fig. 1 | Timeline of national COVID-19 notification systems in Brazil. The REDCap system operated between late January until March 25, 2020. Aggregated numbers from e-SUS-VE and SIVEP-Gripe data for mild and hospitalised COVID-19 cases, respectively, are updated on a daily basis at the *Portal do COVID-19* website (<https://covid.saude.gov.br/>).

Fig. 2 | COVID-19 epidemiology in Brazil. **a.** Number of COVID-19 cases (blue filled line) and deaths (blue dashed line) reported to the Ministry of Health (*Portal do COVID-19* website), and number of COVID-19 confirmed cases (salmon filled line) and number of SARI with unknown aetiology (salmon dashed line) reported to the SIVEP-Gripe database. **b.** First COVID-19 cases by date and Brazilian municipal population size based on the Ministry of Health, from March 28, 2020. Each circle represents the first confirmed COVID-19 case in the municipality (n= 4,196 Brazilian municipalities). **c.** Map coloured according to the number of confirmed COVID-19 cases per state reported to the Ministry of Health (*Portal do COVID-19* website). Circle sizes are proportional to the number of reported COVID-19 deaths in each federal unit. SPBR1 is the first detected SARS-CoV-2 infection in Brazil ⁸. The codes for the 27 federal units in Brazil were: Acre (AC), Alagoas (AL), Amapá (AP), Amazonas (AM), Bahia (BA), Ceará (CE), Distrito Federal (DF), Espírito Santo (ES), Goiás (GO), Maranhão (MA), Mato Grosso (MT), Mato Grosso do Sul (MS), Minas Gerais (MG), Pará (PA), Paraíba (PB), Paraná (PR), Pernambuco (PE), Rio de Janeiro (RJ), Rio Grande do Norte (RN), Rio Grande do Sul (RS), Rondônia (RO), Roraima (RR), Santa Catarina (SC), São Paulo (SP), Sergipe (SE) and Tocantins (TC).

Fig.3 | Estimated R_0 values for four Brazilian states and selected countries. Left, R_0 for the Amazonas, Ceará, Rio de Janeiro and São Paulo states. Right, R_0 for Brazil, France, Italy, Spain and United Kingdom. Daily number of infections used in each analysis can be found in **Extended Figs. 3-4**. Daily number of infections and prior distributions can be found in **Extended Figs. 5-6**.

Fig. 4 | COVID-19, SARI with unknown aetiology and influenza. Red and orange lines indicate cases notified in 2020, blue lines indicate cases notified in 2016 for influenza (filled blue line) and SARI cases with unknown aetiology (dashed blue line). Grey lines indicate influenza and SARI cases with unknown aetiology for 2017, 2018 and 2019.

Fig. 5 | COVID-19 diagnosis and socio-economic factors in the Metropolitan Region of São Paulo. **A.** Spatial distribution of income per capita of MRSP based on census tract of residence. **B.** Distribution of household *per capita* income based on census tract of residence for COVID-19 cases and SARI cases with unknown aetiology. The distribution of average *per capita* income for MRSP as a whole, weighted by population size, is shown on the left. **C.** Posterior mean relative risk of COVID-19 confirmed diagnosis (upper panels) and SARI cases with unknown aetiology (lower panels) for epidemiological weeks 12 (pre-implementation of NPI in São Paulo state, and weeks 16 and 21 (post-implementation of NPI in São Paulo state) (see **Methods** for details).

Fig. 6 | Age-sex structure and clinical features of confirmed COVID-19 cases notified on the SIVEP-Gripe system. **A.** Age classes are shown on the left of the panel. On-going cases were those still active on the SIVEP-Gripe database and without a recorded clinical outcome

761 (death or recovered). **B.** Symptoms, signs and comorbidities of confirmed COVID-19 cases.
762 **C.** Comorbidities among confirmed COVID-19 cases according to age groups and outcome.
763 Confirmed COVID-19 cases with complete comorbidity and outcome (death or recovery)
764 information (n = 15,720). Confirmed COVID-19 cases with complete information on
765 comorbidities and ITU admission (n = 19,409). Horizontal axes show the proportion of
766 patients in each age/outcome stratified with each of the comorbidities recorded.
767